Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms (DECISION)

Recruiting now · Not applicable

Conditions studied: Heart Failure, Cardiovascular Risk Factors

In brief

The DECISION trial aims to evaluate the efficacy of an artificial intelligence (AI)-powered system, Willem™, for improving the detection of heart failure (HF) in primary care settings by interpreting electrocardiograms (ECGs). The study seeks to answer whether AI-assisted ECG interpretation enhances diagnostic accuracy and clinical outcomes compared to standard ECG evaluation in patients with suspected HF or those at high risk. This multicenter, pragmatic, randomized clinical trial involves two groups: patients receiving AI-assisted ECG analysis and those undergoing standard ECG evaluation. The study's primary analysis will compare the diagnostic performance of AI-assisted ECG versus standard ECG using sensitivity, specificity, and predictive value metrics. Secondary analyses will evaluate healthcare resource utilization, clinical outcomes, and usability feedback from healthcare providers. Results will inform the potential integration of AI-assisted ECG in routine primary care workflows for earlier HF detection and better resource allocation.

Key facts

Study ID: NCT07113223
Run by: Idoven 1903 S.L.
People needed: 1968
Starts: 2025-07-23
Expected to finish: 2027-03-01
Last updated by the study team: 2026-07-20

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients with Suspected HF (Group S):
Able to understand and accept the study constraints and to provide informed consent (either themselves or a legal representative).
Age over 65 years (i.e., 65 included).
Presence of symptoms and/or signs typical of Heart Failure (defined by the European Society of Cardiology, ESC), including breathlessness (during activity or at rest, lying down, waking up at night needing to catch their breath), fatigue, swollen ankles/legs, and/or palpitations.
Patients at Risk of Heart Failure due to the presence of cardiovascular (Group R):
Able to understand and accept the study constraints and to provide informed consent (either themselves or a legal representative).
Age over 65 years (i.e., 65 included).
Absence of symptoms and/or signs typical of Heart Failure (defined by the ESC), including breathlessness (during activity or at rest, lying down, waking up at night needing to catch their breath), fatigue, swollen ankles/legs, and/or palpitations.
Presence of at least 1 ACC/AHA Heart Failure risk factor, including hypertension, cardiovascular disease (atrial fibrillation, coronary heart disease or stroke), diabetes, obesity, exposure to cardiotoxic agents, genetic variant for cardiomyopathy, or family history of cardiomyopathy that requires an ECG test for any reason in a primary care center or with an indication of a regular health examination where an ECG is included.

You may not qualify if…

Unwillingness or inability to sign the written informed consent.
Previous Heart Failure diagnosis.
Unavailability or suboptimal quality ECG.

Where it is running

Hospital General Universitario Gregorio Marañón — Madrid, Spain (enrolling)
Hospital Universitario 12 de Octubre — Madrid, Spain (enrolling)
Primary Care: Gerencia Asistencial Atención Primaria Madrid — Madrid, Spain (enrolling)
Hospital Universitario Marqués de Valdecilla — Santander, Spain (enrolling)
Region Stockholm — Stockholm, Sweden (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.